Claus Zieler discusses the Asia Pacific region’s importance to Bayer’s global operations, the company’s commitment to increasing its portfolio of innovative medicines, and the potential for innovation coming from Asian markets.
Having spent four years in Japan previously, how have you had to adapt to serving the entire Asia Pacific region?
"Asia Pacific contributes more than 25% of our global pharmaceuticals sales, which is a significant portion: in 2016, we reported a sales increase of 8.6% to more than €4.8 billion for our Pharmaceuticals Division in the region"
